Publication at Faculty of Medicine in Hradec Králové |
2019
Abstract
Bronchial asthma is a heterogeneous disease whose definition and treatment are based on evidence of variable airway obstruction and inflammation. Despite the enormous increase in information on the pathogenesis of this disease, diagnosis is still an unresolved problem, as we still lack sensitive and specific biomarkers.
On the other hand, at the turn of the 20th and 21st centuries, therapeutic modalities based on the principle of biological therapy developed rapidly. The first authorized drug to meet these characteristics was the omalizumab monoclonal antibody directed against immunoglobulin E (IgE).